Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning l...
Age: 65 years - 66+
Gender: All
7T MRI for Light Therapy in Patients With Mild Cognitive Impairment and Mild AD
The purpose of this research study is to investigate the effect of a light treatment on
sleep, memory and brain function. In people with mild cognitive impairment (MCI) and
Alzheimer's disease, sleep-wake disturbance is evident in up to 60% of patients. This can be
...
Age: 50 - 85 years
Gender: All
Rhythmic Light Therapy for Alzheimer's Disease Patients
The investigator will investigate how light delivering 40 hertz (Hz) affects subjective sleep
and cognition in a controlled laboratory study. A lab study will allow the collection of
electroencephalogram (EEG) data, perform cognitive tests, and observe the response ...
Age: 55 years - 66+
Gender: All
AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid
The primary purpose of this study is to determine whether treatment with lecanemab is
superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite
5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with...
Age: 55 - 80 years
Gender: All
Locus-coeruleus Function in Normal Elderly and AD Risk
Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades
before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed
since midlife. We have previously demonstrated functional vulnerability of the LC to...
Age: 60 - 75 years
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
The Long-term Impact of a Light Intervention on Sleep and Cognition in Mild Cognitive Impairment
To investigate the impact of a long-term light treatment intervention on sleep physiology and
memory in mild cognitively impaired and mild Alzheimer's disease patients living at home. The
goal is also to measure the impact of the lighting intervention on caregivers'...
Age: 50 years - 66+
Gender: All
Light, Metabolic Syndrome and Alzheimer's Disease - Aim 2
To test the long term effect of a light treatment on cognition, sleep and metabolism in
patients with Mild cognitive impairment (MCI) or mild Alzheimer's disease or related dementia
(ADRD).
Age: 55 years - 66+
Gender: All
Light and the Effect on Metabolic Syndrome and Alzheimer's Disease
This study's main hypothesis is that a delivering a tailored lighting intervention (TLI) will
provide a successful means for promoting circadian entrainment and treating metabolic disease
and inflammation in patients with mild cognitive impairment (MCI) and Alzheime...
Age: 55 years - 66+
Gender: All
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol
Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging
Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD.
ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been
...
Age: 55 - 90 years
Gender: All
An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia
The purpose of this study is to evaluate whether treatment with JNJ-54861911 slows cognitive
decline compared with placebo treatment, as measured by a composite cognitive measure, the
Preclinical Alzheimer Cognitive Composite (PACC), in amyloid-positive participants w...
Age: 60 - 85 years
Gender: All